Hantz Financial Services’s Arbutus Biopharma ABUS Stock Holding History

Hantz Financial Services’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1K	Sell	171 -350	-67%	-$1.54K	﹤0.01%	2347
2026 Q1	$2K	Hold	521	–	–	﹤0.01%	2269
2025 Q4	$3K	Buy	521 +171	+49%	+$769	﹤0.01%	2196
2025 Q3	$2K	Hold	350	–	–	﹤0.01%	2139
2025 Q2	$1K	Hold	350	–	–	﹤0.01%	2045
2025 Q1	$1K	Hold	350	–	–	﹤0.01%	1450
2024 Q4	$1K	Hold	350	–	–	﹤0.01%	1011
2024 Q3	$1K	Hold	350	–	–	﹤0.01%	993
2024 Q2	$1K	Hold	350	–	–	﹤0.01%	981
2024 Q1	$1K	Hold	350	–	–	﹤0.01%	1094
2023 Q4	$1K	Hold	350	–	–	﹤0.01%	1055
2023 Q3	$1K	Hold	350	–	–	﹤0.01%	1049
2023 Q2	$1K	Hold	350	–	–	﹤0.01%	1014
2023 Q1	$1K	Hold	350	–	–	﹤0.01%	1031
2022 Q4	$1K	Hold	350	–	–	﹤0.01%	998
2022 Q3	$1K	Hold	350	–	–	﹤0.01%	995
2022 Q2	$1K	Hold	350	–	–	﹤0.01%	973
2022 Q1	$1K	Buy	+350	New	+$1.07K	﹤0.01%	978

Other funds holding ABUS

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Hantz Financial Services's ABUS Position: Q2 2026 in Review

Hantz Financial Services reduced its Arbutus Biopharma (ABUS) stake by 67% in Q2 2026, selling an estimated $1.54K and leaving 171 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2347.

Hantz Financial Services first reported a position in ABUS in Q1 2022 and has held it in 18 quarters since. The position peaked at $3K in Q4 2025. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

Hantz Financial Services held 171 shares of Arbutus Biopharma worth $1K as of Q2 2026.
Hantz Financial Services sold 350 Arbutus Biopharma shares in Q2 2026, an estimated $1.54K.
Arbutus Biopharma made up ﹤0.01% of Hantz Financial Services's portfolio in Q2 2026, its #2347 holding.
Hantz Financial Services first reported a position in Arbutus Biopharma in Q1 2022 and has held it in 18 quarters since.
Hantz Financial Services's Arbutus Biopharma position peaked at $3K in Q4 2025.
177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.